Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287067 | 0.93 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL14582937 | 0.92 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4287200 | 0.91 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL4291113 | 0.88 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL4287691 | 0.87 | MEN1 (0.62) | MEN1KMT2ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL13704122 | 0.87 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL4290980 | 0.86 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL13704149 | 0.86 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL4296680 | 0.86 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL4300461 | 0.84 | KMT2A (0.56) | MEN1KMT2ASMN1; SMN2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | MEN1 4829/4885KMT2A 1440/4885SMN1; SMN2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.